Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).


The mission of SOTIO, the biotechnology company that joined PPF Group in 2012, is to research, develop, and provide access to new and innovative treatment methods for patients suffering from severe forms of cancer.

SOTIO is building a diversified portfolio of cancer treatment products based on its own research and development, cooperation with partners, licensing agreements, investments, and mergers and acquisitions. Teams of top Czech and foreign experts work at SOTIO within the framework of its far-reaching international activities.

SOTIO has the internal capacities it needs for research, clinical development, and product marketing. The company has built its own production and research laboratories in Holešovice, Prague, which are among the most modern and largest of their kind in Europe. SOTIO’s activities are the largest privately-funded research in the medical field in the Czech Republic. SOTIO also has operations in the US, China, Russia, and elsewhere in Europe, such as Switzerland.


SOTIO verifies the safety and efficacy of the products it is developing in a number of phase I to III clinical trials. Since 2012, the company has initiated thirteen clinical studies in Europe and the US focusing on patients with solid tumors, especially those with ovarian, lung, and prostate cancer. SOTIO is the first ever Czech company to reach phase III of clinical development.

SOTIO actively seeks out opportunities to work with other companies and institutions developing promising oncology treatments. It also manages preclinical and clinical development for other biotechnology companies that have contractual or capital ties to PPF Group or SOTIO. One such example is the French company Cytune Pharma. In addition, it manages PPF Group’s investments in English biotechnology company Autolus Therapeutics and Swiss company Cellestia Biotech.

Other Companies

Cytune Pharma SAS

Cytune Pharma is a French biotechnology company researching and developing new therapies designed to strengthen the immune response of patients suffering from cancer and infectious diseases.

Autolus Therapeutics

Autolus Therapeutics is a leader in the development of treatments based on CAR-T cells (genetically engineered T cells). The company is dedicated to the clinical development of a wide portfolio of next-generation T-cell therapies targeting both hematological and solid tumors.     

Cellestia Biotech

Cellestia Biotech was founded in 2014 as a spin-off of the Swiss Federal Institute of Technology Lausanne (EPLF). Cellestia’s lead development compound is CB-103, a novel, first-in-class oral pan-NOTCH inhibitor with an innovative mode of action meant for the treatment of patients with NOTCH-driven lymphomas and solid tumors.


Sale of PPF's Stake in NBE-Therapeutics

At the end of 2020, PPF sold its stake in NBE-Therapeutics, a company developing innovative ADC products for the treatment of solid tumors, to leading global pharmaceutical company Boehringer Ingelheim.

This deal, the largest of its kind in Europe in 10 years, showed the value of the ADCs that SOTIO maintains in its portfolio and that it continues to develop. These products could reach their first patients by the end of 2021 in the first phase of clinical trials.

"SOTIO exemplifies the world-class standard of Czech science in its mission and results. Our efforts are focused on finding a cure for cancer."

Radek Špíšek



SOTIO a.s.

Jankovcova 1518/2
170 00 Praha 7
Czech Republic


Strawinskylaan 933
1077 XX Amsterdam
The Netherlands